URGN(UroGen Pharma Ltd.) · 财务报表

URGN(UroGen Pharma Ltd.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$48.04M$64.36M$82.71M$90.40M$109.79M
毛利润$42.88M$56.70M$73.35M$81.52M$97.34M
营业利润−$92.29M−$79.04M−$65.54M−$96.78M−$124.86M
净利润−$110.82M−$109.78M−$102.24M−$126.87M−$153.49M
经营现金流−$84.89M−$87.56M−$76.38M−$96.77M−$162.44M
自由现金流−$85.64M−$87.81M−$76.57M−$97.06M−$162.73M
摊薄每股收益$-4.96————

UroGen Pharma Ltd. URGN